Cowen Starts Voyager Therapeutics (VYGR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Chardan Capital Markets Starts Voyager Therapeutics (VYGR) at Sell
December 9, 2015 9:55 AM ESTChardan Capital Markets initiated coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Sell rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.
Shares of Voyager Therapeutics closed at $30.11 yesterday.
... MoreWedbush Starts Voyager Therapeutics (VYGR) at Outperform
December 7, 2015 7:42 AM ESTWedbush initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Outperform rating and a price target of $36.00.
Analyst David Nierengarten highlighted:
Pioneering AAV-based gene therapy for serious diseases of the central nervous system (CNS). VYGR has selected a number of CNS diseases with validated, specific gene targets that are amenable to AAV gene therapy. The CNS represents an ideal site for gene therapy due to its immune privilege status and terminally-differentiated cells that allow long-term transgene... MorePiper Jaffray Starts Voyager Therapeutics (VYGR) at Overweight
December 7, 2015 6:35 AM ESTPiper Jaffray initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Overweight rating and a price target of $47.00.
Analyst Joshua E. Schimmer commented, "We are initiating coverage of VYGR with an OW rating and $47 PT based on a DCF analysis through 2022 with an 11%... More
